Aurinia Pharmaceuticals Inc. Increase (Decrease) in Accounts Payable
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase (Decrease) in Accounts Payable of -$3.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$2.80M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$652.00K.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.10M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.10M, a 337.15% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.87M, a 317.91% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2024 was $860.00K, a 30.65% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2023 was $1.24M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable for fiscal 2022 was -$792.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.45M 10-Q · filed 2026-08-06 | -$2.35M derived: sum of 3 quarters · filed 2026-08-06 | -$3.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$652.00K 10-Q · filed 2026-05-07 | $447.00K derived: sum of 2 quarters · filed 2026-05-07 | -$651.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.00K derived: sum of 2 quarters · filed 2026-02-26 | -$900.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.87M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.00M derived: sum of 2 quarters · filed 2026-08-06 | -$2.97M 10-Q · filed 2025-11-04 | -$6.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$901.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.88M 10-Q · filed 2026-08-06 | -$5.57M derived: sum of 3 quarters · filed 2026-08-06 | -$5.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$974.00K 10-Q · filed 2026-05-07 | -$4.67M derived: sum of 2 quarters · filed 2026-05-07 | -$4.20M derived: sum of 3 quarters · filed 2026-05-07 | -$1.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.23M derived: sum of 2 quarters · filed 2026-02-26 | -$485.00K derived: sum of 3 quarters · filed 2026-02-26 | $860.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $463.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.21M derived: sum of 2 quarters · filed 2025-11-04 | $4.55M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $4.09M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $1.34M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $1.24M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$792.00K 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |